SAR Clinical Trial
Official title:
A Phase I Trial to Assess Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) (CCT301-38) in Patients With Relapsed or Refractory AXL Positive Sarcomas
This clinical study is to investigate the safety and tolerability of CCT301-38 CAR modified autologous T cells (CCT301-38) in subjects with relapsed or refractory AXL positive sarcomas
This study is an open label, single-center Phase I dose escalation trial to assess the safety, tolerability, DLT and MTD of CCT301-38 cell therapy in patients with AXL positive relapsed or refractory sarcomas. Subjects that meet inclusion criteria with positive AXL biopsy (IHC 1+ or greater in ≥50% tumor cells) will receive CCT301-38 according to the 3+3 dose escalation design. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04621058 -
Efficacy of Vitamin D Treatment in Mortality Reduction Due to COVID-19.
|
Phase 3 | |
| Completed |
NCT04535856 -
Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients
|
Phase 1 | |
| Completed |
NCT01307319 -
Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies
|
Phase 3 | |
| Completed |
NCT02932774 -
Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)
|
Phase 4 | |
| Not yet recruiting |
NCT04777981 -
(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC
|
N/A |